Prescription medicine
Methsuximide Brand names: Celontin
Methsuximide (Celontin) is a prescription medicine with an FDA approval on record since 1957. A generic is approved and listed by 1 labeler, but in the October 7, 2026 NADAC survey pharmacies bought only the brand, at $4.40 per Celontin 300 mg capsule.
- Generic approved
Check it at the source: the methsuximide FDA label on DailyMed (effective April 7, 2026, Parke-Davis Div of Pfizer Inc); the NDA 10596 record on Drugs@FDA; every methsuximide label on DailyMed.
Highlights of the record
FDA label of April 7, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageCelontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.
Forms and strengths
- 300 mg
Capsule.
On the market
- Earliest approval on file
- February 8, 1957 Celontin, Parke Davis; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first May 1, 2023; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 1 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $4.40 per capsule Celontin 300 mg capsule
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 181 through July 30, 2026
What is methsuximide used for?
From the label: indications and usageCelontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.
Conditions named in the indications of methsuximide's FDA labels, with every medicine labeled for each:
From other methsuximide labelsSeizures and epilepsy: INDICATIONS AND USAGE Celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.
FDA pharmacologic class: Anti-epileptic Agent.
Source: FDA drug label (Celontin), Parke-Davis Div of Pfizer Inc, effective April 7, 2026 (SPL set 64a6ee88-c6b1-4e13-8208-b6772ef65a74), via openFDA; the full label on DailyMed
What does the patient leaflet for methsuximide say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about CELONTIN?Do not stop taking CELONTIN without first talking to your healthcare provider. Stopping CELONTIN suddenly can cause serious problems. CELONTIN can cause serious side effects, including: 1. Rare but serious blood problems that may be life-threatening. Call your healthcare provider right away if you have: o fever, swollen glands, or sore throat that come and go or do not go away o frequent infections or an infection that does not go away o easy bruising o red or purple spots on your body o bleeding gums or nose bleeds o severe fatigue or weakness 2. Systematic Lupus Erythematosus. Call your healthcare provider right away if you have any of these symptoms: o joint pain and swelling o muscle pain o fatigue o low-grade fever o pain in the chest that is worse with breathing o unexplained skin rash 3. Like other antiepileptic drugs, CELONTIN may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: o thoughts about suicide or dying o attempts to commit suicide o new or worse depression o new or worse anxiety o feeling agitated or restless o panic attacks o trouble sleeping (insomnia) o new or worse irritability o acting aggressive, being angry, or violent o acting on dangerous impulses o an extreme increase in activity and talking (mania) o other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? o Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. o Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. […]
From the patient leaflet: What should I avoid while taking CELONTIN?Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking CELONTIN without first discussing this with your healthcare provider. CELONTIN taken with alcohol or medicines that cause sleepiness or dizziness may make your sleepiness or dizziness worse. • Do not drive, operate heavy machinery, or do other dangerous activities until you know how CELONTIN affects you. CELONTIN can slow your thinking and motor skills.
From the patient leaflet: How should I store CELONTIN?Store CELONTIN at room temperature, between 59°F to 86°F (15°C to 30°C). • Keep CELONTIN capsules in a dry place. • Keep CELONTIN out of the light. • Protect CELONTIN from heat. • Do not use CELONTIN capsules that if they do not look full or if the contents have melted. Keep CELONTIN and all medicines out of the reach of children.
Source: FDA drug label (Celontin), Parke-Davis Div of Pfizer Inc, effective April 7, 2026 (SPL set 64a6ee88-c6b1-4e13-8208-b6772ef65a74), via openFDA; the full label on DailyMed
Is there a generic for methsuximide (Celontin)?
The FDA approved the first generic methsuximide on May 1, 2023. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists methsuximide from 1 labeler under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it. In the latest NADAC survey pharmacies bought only the brand, so a generic may not be on sale yet.
- 1957 earliest approval on file
- 2023 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for methsuximide (Celontin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $4.40 per Celontin 300 mg capsule, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Celontin 300 mg capsule (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Celontin 300 mg capsule | Brand | $4.40 per capsule | $132.06 | +0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the methsuximide label say about other medicines?
The methsuximide label names 2 other medicines in its interaction, contraindication or warning sections. The labels of 3 other medicines name methsuximide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Phenobarbital | drug interactions | Drug Interactions Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, methsuximide may increase the plasma concentrations of phenytoin and phenobarbital). |
| Phenytoin | drug interactions | Drug Interactions Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, methsuximide may increase the plasma concentrations of phenytoin and phenobarbital). |
Other labels that name methsuximide
Source: FDA drug label (Celontin), Parke-Davis Div of Pfizer Inc, effective April 7, 2026 (SPL set 64a6ee88-c6b1-4e13-8208-b6772ef65a74), via openFDA; the full label on DailyMed
What do FAERS reports show for methsuximide?
The FDA Adverse Event Reporting System holds 181 reports that list methsuximide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 39 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as methsuximide?
20 other medicines are given the same way (oral) and in the same FDA class as methsuximide or labeled mainly for the same use (seizures and epilepsy), the same class first. Seizures and epilepsy lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Gabapentin | Seizures and epilepsy | 87 labelers | $0.0218 per capsule 100 mg capsule | No current entry |
| Lamotrigine | Seizures and epilepsy | 50 labelers | $0.0268 per tablet 25 mg tablet | A presentation being discontinued |
| Divalproex | Seizures and epilepsy | 44 labelers | $0.194 per tablet 500 mg tablet | No current entry |
| Oxcarbazepine | Seizures and epilepsy | 43 labelers | $0.167 per tablet 300 mg tablet | No current entry |
| Zonisamide | Seizures and epilepsy | 20 labelers | $0.106 per capsule 100 mg capsule | No current entry |
| Valproic acid | Seizures and epilepsy | 19 labelers | $0.243 per capsule 250 mg capsule | Listed; available |
| Phenytoin | Seizures and epilepsy | 23 labelers | $0.145 per capsule 100 mg capsule | No current entry |
| Primidone | Seizures and epilepsy | 21 labelers | $0.0914 per tablet 50 mg tablet | No current entry |
Every medicine labeled for the same conditions as methsuximide
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to methsuximide
- 20 medicines for the same use
- Other anti-seizure medicines
- the pharmacologic class, with prices and generics
- Methsuximide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other